Predictive biomarkers for checkpoint inhibitor-based immunotherapy von Gibney, Geoffrey T, Dr, Weiner, Louis M, Prof, Atkins, Michael B, Prof

Volltext

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma von Atkins, Michael B., Tannir, Nizar M.

Volltext

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies von Philips, George K, Atkins, Michael

Volltext

Resistance to targeted therapy in renal-cell carcinoma von Rini, Brian I, Dr, Atkins, Michael B, Prof

Volltext

Checkpoint inhibitor immunotherapy in kidney cancer von Xu, Wenxin, Atkins, Michael B., McDermott, David F.

Volltext

Toxicities of Immunotherapy for the Practitioner von Weber, Jeffrey S, Yang, James C, Atkins, Michael B, Disis, Mary L

Volltext

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives von Atkins, Michael B, Larkin, James

Volltext

Which drug, and when, for patients with BRAF-mutant melanoma? von Jang, Sekwon, MD, Atkins, Michael B, Prof

Volltext

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade von Motzer, Robert J., Banchereau, Romain, Hamidi, Habib, Powles, Thomas, McDermott, David, Atkins, Michael B., Escudier, Bernard, Liu, Li-Fen, Leng, Ning, Abbas, Alexander R., Fan, Jinzhen, Koeppen, Hartmut, Lin, Jennifer, Carroll, Susheela, Hashimoto, Kenji, Mariathasan, Sanjeev, Green, Marjorie, Tayama, Darren, Hegde, Priti S., Schiff, Christina, Huseni, Mahrukh A., Rini, Brian

Volltext

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain von Tawbi, Hussein A, Forsyth, Peter A, Algazi, Alain, Hamid, Omid, Hodi, F. Stephen, Moschos, Stergios J, Khushalani, Nikhil I, Lewis, Karl, Lao, Christopher D, Postow, Michael A, Atkins, Michael B, Ernstoff, Marc S, Reardon, David A, Puzanov, Igor, Kudchadkar, Ragini R, Thomas, Reena P, Tarhini, Ahmad, Pavlick, Anna C, Jiang, Joel, Avila, Alexandre, Demelo, Sheena, Margolin, Kim

Volltext

Systemic Therapy for Melanoma: ASCO Guideline von Seth, Rahul, Messersmith, Hans, Kaur, Varinder, Kirkwood, John M, Kudchadkar, Ragini, McQuade, Jennifer Leigh, Provenzano, Anthony, Swami, Umang, Weber, Jeffrey, Alluri, Krishna C, Agarwala, Sanjiv, Ascierto, Paolo A, Atkins, Michael B, Davis, Nancy, Ernstoff, Marc S, Faries, Mark B, Gold, Jason S, Guild, Samantha, Gyorki, David E, Khushalani, Nikhil I, Meyers, Michael O, Robert, Caroline, Santinami, Mario, Sehdev, Amikar, Sondak, Vernon K, Spurrier, Gilliosa, Tsai, Katy K, van Akkooi, Alexander, Funchain, Pauline

Volltext

PD‐1 as a potential target in cancer therapy von McDermott, David F., Atkins, Michael B.

Volltext

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial von Haas, Naomi B, Dr, Manola, Judith, MS, Uzzo, Robert G, Prof, Flaherty, Keith T, MD, Wood, Christopher G, Prof, Kane, Christopher, Prof, Jewett, Michael, Prof, Dutcher, Janice P, Prof, Atkins, Michael B, Prof, Pins, Michael, Prof, Wilding, George, Prof, Cella, David, Prof, Wagner, Lynne, Prof, Matin, Surena, Prof, Kuzel, Timothy M, Prof, Sexton, Wade J, Prof, Wong, Yu-Ning, MD, Choueiri, Toni K, MD, Pili, Roberto, Prof, Puzanov, Igor, MD, Kohli, Manish, MD, Stadler, Walter, Prof, Carducci, Michael, Prof, Coomes, Robert, DiPaola, Robert S, Prof

Volltext

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG) von Anker, Christopher J., MD, Grossmann, Kenneth F., MD, PhD, Atkins, Michael B., MD, Suneja, Gita, MD, Tarhini, Ahmad A., MD, PhD, Kirkwood, John M., MD

Volltext

Bounds on the nonminimal coupling of the Higgs boson to gravity von Atkins, Michael, Calmet, Xavier

Volltext

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, p... von Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, Rini, Brian I

Volltext

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma von Rini, Brian I, Plimack, Elizabeth R, Stus, Viktor, Gafanov, Rustem, Hawkins, Robert, Nosov, Dmitry, Pouliot, Frédéric, Alekseev, Boris, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Kryzhanivska, Anna, Bondarenko, Igor, Azevedo, Sergio J, Borchiellini, Delphine, Szczylik, Cezary, Markus, Maurice, McDermott, Raymond S, Bedke, Jens, Tartas, Sophie, Chang, Yen-Hwa, Tamada, Satoshi, Shou, Qiong, Perini, Rodolfo F, Chen, Mei, Atkins, Michael B, Powles, Thomas

Volltext

Update on the DREAMseq trial in melanoma von Atkins, Michael B

Volltext

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma von Motzer, Robert J, Penkov, Konstantin, Haanen, John, Rini, Brian, Albiges, Laurence, Campbell, Matthew T, Venugopal, Balaji, Kollmannsberger, Christian, Negrier, Sylvie, Uemura, Motohide, Lee, Jae L, Vasiliev, Aleksandr, Miller, Wilson H, Gurney, Howard, Schmidinger, Manuela, Larkin, James, Atkins, Michael B, Bedke, Jens, Alekseev, Boris, Wang, Jing, Mariani, Mariangela, Robbins, Paul B, Chudnovsky, Aleksander, Fowst, Camilla, Hariharan, Subramanian, Huang, Bo, di Pietro, Alessandra, Choueiri, Toni K

Volltext

The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma von Shoushtari, Alexander N., Munhoz, Rodrigo R., Kuk, Deborah, Ott, Patrick A., Johnson, Douglas B., Tsai, Katy K., Rapisuwon, Suthee, Eroglu, Zeynep, Sullivan, Ryan J., Luke, Jason J., Gangadhar, Tara C., Salama, April K. S., Clark, Varina, Burias, Clare, Puzanov, Igor, Atkins, Michael B., Algazi, Alain P., Ribas, Antoni, Wolchok, Jedd D., Postow, Michael A.

Volltext